Madrigal Pharmaceuticals (MDGL) stock
Follow MDGL's trial news. Pro members can get an alert when Madrigal Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
What's next for MDGL, and how long its cash lasts
From Madrigal Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Its trials
Cash runway
$839M in cash
Dilution on the horizon
- Shelf registration (S-3ASR, filed May 7, 2024)
- At-the-market share sales program (S-3ASR, filed May 7, 2024)
Insiders
CEO William John Sibold sold 11,583 shares on Sep 11, under a planned sale. 20 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why MDGL scores 4
Below AverageTransition, 1 of 14 checks firingWhat the Quality Score means
Well below its own recent run. MDGL scores 4 today, against a median of 8.5 over its last 20 recorded sessions.
- −1Profit Lost $325M over the last four quarters, more than the $282M lost a year earlier, from the SEC filings
- +3Growth sales up 149% on the year, operating margin up 35.0 points
- Chart checks adds
- Long-term trend adds
- Size adds
- Cash flow subtracts
What's next
Expected to report Wed Nov 4, before the open
After its last 4 reports it closed -1.4% on average, higher 2 of 4 times.
What would turn MDGL's score around: 6 things, for Pro members
Here is what Pro members see.
Every stock has a live page like this, MDGL included: the price in real time, the full chart, all 14 checks, and every line of its score.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
MDGL has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1436.5
- MACD (12, 26, 9)Below signal
- 50-day average$523.25
- 200-day average$510.61
- ADX 1418.3
- Support$499.34
- Resistance$499.55
- Bollinger Bands (20, 2)Inside
- Volume1.3x
How MDGL ranks in Biotech
MDGL is #89 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
EXEL7/1417
AMRX6/1417
MAIAOpen for its score
MAZEOpen for its score
MEDPOpen for its score
MIRMOpen for its score
MDGL1/144
When does MDGL report earnings, and what happens after?
Expected to report Wed Nov 4, before the open (in 33 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Jul 30, 2026Before open | Before open | -7.6% | -9.8% | -6.0% |
| May 6, 2026Before open | Before open | +5.7% | +7.4% | +1.6% |
| Feb 19, 2026Before open | Before open | -8.0% | -11.1% | -11.5% |
| Nov 4, 2025Before open | Before open | -1.5% | +7.8% | +20.3% |
Who is trading MDGL
MDGL insider trades
2 insiders sold $1.7M across 11 filings in the last 6 months. No open-market buys on record. The newest:
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of MDGL's score, with the points and the reason
- All 14 checks on MDGL and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on MDGL
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.